Synairgen stock rockets as inhaled interferon-beta shows signs of efficacy in COVID-19 July 20, 2020 By Cormac Sheridan No Comments DUBLIN – Synairgen plc has detected what appear to be promising efficacy signals in a phase II trial of its inhaled formulation of interferon-beta 1a, SNG-001, in hospitalized COVID-19 patients.Read More